Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of baxdrostat + dapagliflozin versus dapagliflozin alone for prevention of heart failure events in high-risk adults
MOH_2025-02-16_013920Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing baxdrostat + dapagliflozin with placebo + dapagliflozin (2 arms). Primary endpoint: Composite of heart failure events and cardiovascular death. Started Feb 2025; status: recruiting.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on MOH_2025-02-16_013920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-16_013920.